ReviewFrontiers in public health2024
Carbapenem-resistant Gram-negative bacteria (CR-GNB) in ICUs: resistance genes, therapeutics, and prevention - a comprehensive review.
Review in Frontiers in public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 24 citations in OpenAlex.
- Five years of wastewater surveillance reveal COVID-19-Associated amplification and seasonal shifts inOne health (Amsterdam, Netherlands) · 2026Article
- Modeling Phage-Antibiotic Synergy, Innate Immunity, and Phage Resistance in Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Molecular and Structural Insights ofAntibiotics (Basel, Switzerland) · 2026Article
- Molecular characterization of β-lactamase genes and porin alterations in multidrug-resistant Gram-negative clinical isolates from Calabria, Southern Italy.Molecular biology reports · 2026Article
- Multicenter Point-Prevalence Study of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Molecular characteristics and analysis of drug resistance-virulence correlation of carbapenem-resistantMicrobiology spectrum · 2026Article
- Trends and drivers of multidrug-resistant bacteria incidence in 59 Chilean intensive care units, 2015-2024: a Bayesian hierarchical analysis.Lancet regional health. Americas · 2026Article
- Clinical distribution and drug resistance of carbapenem-resistant Pseudomonas aeruginosa infection in Eastern China from 2019 to 2024.BMC infectious diseases · 2026Article
- Burden and resistance of Gram-negative pathogens in ICU-acquired infections in Vietnam: a cross-sectional study.Iranian journal of microbiology · 2026Article
- From Laboratory to Clinic: Translational Medicine Paradigm of Polymyxin B Nanopreparations for Overcoming Drug-Resistant Bacterial Infections.International journal of nanomedicine · 2026Review
- Real-World Experience with High- versus Low-Dose Polymyxin B for Pulmonary Infections: A Retrospective Cohort Study.Infection and drug resistance · 2026Article
- Early trajectories of antibiotic exposure and colonization pressure and risk of ICU-acquired carbapenem-resistant Gram-negative bacteria: A prospective cohort study.Annals of intensive care · 2026Article
- Pathogen characteristics and pre-index clinical factors associated with multidrug-resistant organism infections in intensive care unit patients.Frontiers in public health · 2026Observational
- Synergistic Effects of Amikacin With Imipenem and Ciprofloxacin Against Multidrug-Resistance UropathogenicThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Article
- Clinical Characteristics and Outcomes of Carbapenem-Resistant Gram-Negative Bacteria Pneumonia in Immunocompromised ICU Patients: A Retrospective Study.Infection and drug resistance · 2026Article
- The Evolving Triad of Carbapenem Resistance: Emergence of Dominant CRPA, Persistent CRAB, and Rebounding CRKP in a Chinese Regional Hospital (2020-2024).Infection and drug resistance · 2026Article
- Spectrum, dose, and duration of antibiotic exposure and risk of intensive care unit-acquired carbapenem-resistant gram-negative bacteria: a prospective cohort study.Annals of intensive care · 2025Article
- Molecular Epidemiological Surveillance of Carbapenem-Resistant Gram-Negative Bacteria in Southern Lebanon.Antibiotics (Basel, Switzerland) · 2025Article
- The impact of carbapenem-resistant infections in intensive care units: focus on non-fermenting gram-negative bacilli and survival analysis.Antimicrobial resistance and infection control · 2025Article
- Distribution of MBL and serine-β-lactamase-producing pathogens in ventilator-associated pneumonia: insights into MDR and XDR strains.Iranian journal of microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intensive care units (ICUs) are specialized environments dedicated to the management of critically ill patients, who are particularly susceptible to drug-resistant bacteria. Among these, carbapenem-resistant Gram-negative bacteria (CR-GNB) pose a significant threat endangering the lives of ICU patients. Carbapenemase production is a key resistance mechanism in CR-GNB, with the transfer of resistance genes contributing to the extensive emergence of antimicrobial resistance (AMR). CR-GNB infections are widespread in ICUs, highlighting an urgent need for prevention and control measures to reduce mortality rates associated with CR-GNB transmission or infection. This review provides an overview of key aspects surrounding CR-GNB within ICUs. We examine the mechanisms of bacterial drug resistance, the resistance genes that frequently occur with CR-GNB infections in ICU, and the therapeutic options against carbapenemase genotypes. Additionally, we highlight crucial preventive measures to impede the transmission and spread of CR-GNB within ICUs, along with reviewing the advances made in the field of clinical predictive modeling research, which hold excellent potential for practical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.